A double blind trial of dipyridamole in CAPD.
Since we had previously shown that dipyridamole augmented inulin and glucose clearance during intermittent peritoneal dialysis we sought to extend our study to the patient undergoing continuous ambulatory peritoneal dialysis. We carried out a double blind study in which patients received either 75 mg of active drug or placebo for a 2-week period. At the end of this period the mass transfer coefficients, between plasma and dialysate, were measured for selected solutes. We did not find any drug effect. The results of our first study together with the results of this study suggest that dipyridamole has no place in the chronic management of patients undergoing peritoneal dialysis.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D010531:Peritoneal Dialysis, Continuous Ambulatory
D004176:Dipyridamole